ACNB is a financial holding company. The company provides banking, insurance, and financial services to businesses and consumers through its wholly-owned subsidiaries, ACNB Bank (the Bank) and Russell Insurance Group, Inc. (RIG). The Bank engages in commercial and consumer banking and wealth management services through its community banking office locations in Adams, Cumberland, Franklin, and York Counties, PA. Through its nonbanking subsidiary, RIG, the company provides a range of property and casualty and group life and health insurance to both commercial and individual clients.

Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Amerant Bancorp is a bank holding company. Through its subsidiary, Amerant Bank, N.A. (the Bank), the company provides individuals and businesses an array of deposit, credit, investment, wealth management, retail banking and fiduciary services. The company provides a range of deposit products and services, including a variety of checking and savings accounts, certificates of deposit, money market accounts, debit cards, remote deposit capture, online banking, mobile banking, e-Statements and direct deposit services. The company also provides a variety of trust and estate planning products and services through the Bank's subsidiaries, Amerant Trust, N.A. and Elant Bank & Trust Ltd.

AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, the company's anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. The company's wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies.

UFP Technologies is a designer and custom manufacturer of components, subassemblies, products and packaging utilizing foams, films, and plastics primarily for the medical market. The company's single-use and single-patient devices and components are used in a range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging. The company also provides engineered products and components to customers in the automotive, aerospace and defense, consumer, electronics and industrial markets such as military uniform and gear components, automotive interior trim, and protective packaging, among other.

Uranium Energy is engaged in uranium mining and related activities, including exploration, pre-extraction, extraction and processing, on uranium projects located in the United States and Paraguay. The company utilizes in-situ recovery (ISR) mining, which involves circulating oxidized water through an underground uranium deposit, dissolving the uranium and then pumping the uranium-rich solution to the surface for processing. The company has one uranium mine located in the State of Texas, the Palangana Mine, which utilizes ISR mining and has commenced extraction of uranium oxide, or yellowcake. The company has one uranium processing facility located in the State of Texas, the Hobson Processing Facility.